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Summary
Background.  —  The  small  diameter  Sprint  Fidelis  deﬁbrillation  lead  has  not  been  implanted  in
patients since  2007  due  to  its  unusually  high  rate  of  fracture.  Predictors  of  lead  fracture  riskRisk  factors;
Inappropriate
therapies;
Deﬁbrillator
were identiﬁed  in  several  studies,  mainly  in  North  American  studies.
Aim. —  We  established  a  multicentre  registry  to  determine  the  lead  fracture  rate  and  predictors
of fracture  in  a  large  cohort  of  French  patients.
Methods.  —  Nine  hundred  and  eighty-six  patients  implanted  with  a  Sprint  Fidelis  lead  at  six
centres between  December  2004  and  November  2007  were  included  in  this  registry.
Abbreviations: ARVD, arrhythmogenic right ventricular dysplasia; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchro-
ization therapy plus deﬁbrillator; ICD, implantable cardioverter-deﬁbrillator; LIA, lead integrity alert; LVEF, left ventricular ejection
raction.
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Results.  —  Over  a  mean  follow-up  of  51.4  ±  20  months,  the  mean  fracture  rate  was  11.2%,  and
increased over  time:  1.2%  at  1  year,  3.8%  at  2  years,  7.4%  at  3  years,  13.9%  at  4  years,  and  20.7%
at 5  years.  In  multivariable  analysis,  younger  age  (<  40  years)  was  associated  with  a  higher  risk
of fracture  compared  to  patients  <  40  years,  patients  aged  between  40—60  years  had  a  relative
risk of  0.53  (95%  conﬁdence  interval  [CI]  0.29—0.98)  and  patients  >  60  years  had  a  relative  risk
of 0.45  (95%  CI  0.24—0.84)  and  subpectoral  implantation  (at  3  years)  with  a  relative  risk  of
2.35 (95%  CI  1.29—4.28).  Lead  model  6930  (single-coil,  passive-ﬁxation)  had  a  relative  risk  of
3.47 (95%  CI  1.13—10.7)  compared  with  the  6949  model  (double  coil,  active-ﬁxation).  No  other
predictor of  fracture  was  identiﬁed.
Conclusions.  —  In  a  large  multicentre  cohort  of  French  patients  implanted  with  a  Sprint  Fidelis
electrode, the  fracture  rate  remains  high,  especially  in  young  patients  with  submuscular  implant
and the  6930  electrode  model.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — L’électrode  de  déﬁbrillation  Sprint  Fidelis  de  petit  diamètre  n’est  plus  implantée
depuis 2007  compte  tenu  d’un  taux  anormalement  élevé  de  fracture.  Les  facteurs  prédictifs  du
risque de  fracture  de  cette  électrode  ont  été  évalués  dans  plusieurs  études,  principalement
chez des  patients  d’Amérique  du  Nord.
Objectif.  —  Nous  avons  mis  en  place  un  registre  multicentrique  pour  déterminer  le  taux  de
fracture et  les  facteurs  prédictifs  de  fracture  dans  une  grande  cohorte  de  patients  franc¸ais.
Méthodes.  —  Neuf  cent  quatre-vingt-six  patients  implantés  d’une  électrode  Sprint  Fidelis  entre
décembre 2004  et  novembre  2007  ont  été  inclus.
Résultats.  —  Avec  un  suivi  moyen  de  51,4  mois,  le  taux  de  fractures  a  été  de  1,2  %,  3,8  %,  7,4  %,
13,9 %,  20,7  %  à  respectivement  1,  2,  3,  4  et  5  ans.  En  analyse  multivariée,  l’âge  jeune  (moins
de 40  ans)  était  associé  à  un  risque  plus  élevé  de  fracture  (comparés  aux  patients  âgés  de  moins
de 40  ans),  ceux  âgés  entre  40  et  60  ans  ont  un  risque  relatif  de  0,53  (intervalle  de  conﬁance
95 %  [IC]  0,29—0,98)  et  ceux  âgés  de  plus  de  60  ans  ont  un  risque  relatif  de  0,53  (IC  0,24—0,84),
l’implantation  en  rétro-pectoral  à  un  risque  relatif  de  2,35  (95  %  IC  1,29—4,28)  à  3  ans.  Le
modèle d’électrode  6930  (simple  coil  à  ﬁxation  passive)  a  un  risque  de  3,47  (95  %  IC  1,13—10,7)
en comparaison  au  modèle  6949  (double  coil  à  ﬁxation  active).  Aucun  autre  facteur  prédictif
n’a été  identiﬁé.
Conclusions.  —  Dans  une  cohorte  importante  multicentrique  franc¸aise  de  patients  implantés
d’une électrode  Sprint  Fidelis,  le  taux  de  fracture  reste  élevé,  surtout  chez  les  patients  jeunes,
avec implantation  rétro-pectorale  et  le  modèle  6930  de  cette  électrode.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Large  randomized  trials  have  shown  the  beneﬁcial  effects  of
the  implantable  cardioverter-deﬁbrillator  (ICD)  on  mortality
in  both  primary  [1—5]  and  secondary  [6,7]  prevention  of  sud-
den  cardiac  death.  In  addition,  the  advent  of  transvenous
ICD  leads  more  than  20  years  ago  is  responsible  for  the  20-
fold  increase  in  annual  implantations  over  the  past  20  years
[8],  with  more  than  120,000  devices  implanted  each  year
worldwide.
Both  ICD  generators  and  leads  are  critical  components  of
the  system.  Whereas  generator  failures  are  relatively  easy  to
handle,  lead  failures  may  have  more  severe  consequences,
such  as  failure  to  pace  or  to  deﬁbrillate,  inappropriate  shock
delivery  and  even  death;  furthermore,  lead  removal  may  be
dangerous.  Since  the  ﬁrst  introduction  of  endocardial  ICD
ﬁ
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ceads  in  1990,  there  has  been  a progressive  reduction  in
ead  size  to  simplify  implantation.  Medtronic  Sprint  Fidelis
eads  (Medtronic  Inc.,  Minneapolis,  MN,  USA)  were  released
n  2004  and  were  immediately  used  extensively  worldwide
ecause  of  their  small  size  (6.6  F).  In  April  2007,  Hauser
t  al.  [9]  reported  a  signiﬁcant  incidence  of  Sprint  Fidelis
ead  fractures,  and  in  November  2007,  Medtronic  stopped
elease  of  the  Sprint  Fidelis  lead.  Since  then,  Medtronic,
he  Food  and  Drug  Administration  and  other  health  authori-
ies  have  published  speciﬁc  recommendations  for  follow-up
n  patients  with  a  Sprint  Fidelis  lead  [10].
Since  2009,  several  independent  registries  have  con-
rmed  a  high  incidence  of  Sprint  Fidelis  lead  fracture
11,12].  However,  these  included  single-centre  studies
eporting  a  higher  rate  of  fracture  in  the  Sprint  Fidelis  lead
ompared  with  that  in  other  leads  [12]  and  a multicentre
2 O.  Piot  et  al.
r
t
l
p
A
d
r
M
A
F
D
D
T
l
i
L
s
i
v
a
t
[
s
l
u
a
(
t
f
t
a
a
l
c
p
S
S
I
u
e
e
t
s
p
i
a
t
v
m
s
Table  1  Baseline  characteristics  of  patients  in  the
French  Fidelis  registry.
Variable
Age  at  implantation  (years)  60.9  ±  10.6
Men  809  (82)
Primary  prevention  576  (58)
Heart  disease  (group  1,  n  =  843;  group  2,
n  =  143)
Ischaemic  517  (52)
Dilated  326  (33)
Hypertrophic  cardiomyopathy 27  (3)
Electrical  23  (2)
ARVD  27  (3)
Others,  none  66  (7)
LVEF  0.32
(0.15—0.70)
LVEF  stratiﬁcation
<  0.35  642  (55)
0.35—0.55  232  (24)
>  0.55  112  (12)
Cardiac  resynchronization  therapy  369  (37)
Sprint  Fidelis  lead  model
6930  (single-coil,  passive-ﬁxation  lead)  18  (2)
6931  (single-coil,  active-ﬁxation  lead)  525  (53)
6948  (dual-coil,  passive-ﬁxation  lead)  60  (6)
6949  (dual-coil,  active-ﬁxation  lead)  383  (39)
Venous  access
Cephalic  628  (64)
Subclavian  358  (36)
Left  side  location  763  (79)
Device  location
Prepectoral  876  (89)
Subpectoral  110  (11)
RV  lead  position
Apex  819  (83)
Septal  167  (17)
Number  of  leads  implanted
1  301  (31)
2  374  (37)
3  311  (32)
Data are mean ± standard deviation, number (%) or mean
(range); ARVD: arrhythmogenic right ventricular dysplasia;
LVEF: left ventricular ejection fraction; RV: right ventricle.
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egistry  conﬁrming  the  high  rate  of  Sprint  Fidelis  lead  frac-
ure  (mainly  dual-coil  leads)  in  North  America  [11].
We  report  the  results  of  a  the  French  Fidelis  registry,
aunched  at  the  end  of  2011  and  conducted  under  the  aus-
ices  of  the  French  Working  Group  on  Cardiac  Pacing  and
rrhythmia.  This  registry  not  only  aimed  to  report  the  inci-
ence  of  lead  fracture,  but  also  to  determine  the  potential
isk  factors  for  developing  such  a  lead  fracture.
ethods
ll  patients  implanted  with  a  Sprint  Fidelis  lead  in  six  large
rench  ICD  centres  (Grenoble,  Lille,  Nancy,  Rennes,  Saint-
enis  and  Saint-Etienne)  were  included  in  the  registry.
ata collection
he  following  demographic  data  were  collected:  age;  sex;
eft  ventricular  ejection  fraction  (LVEF;  subsequently  strat-
ﬁed  into  LVEF  <  0.35,  LEVF  between  0.35  and  0.55  and
VEF  >  0.55);  indication  for  implantation  (prophylactic  or
econdary  indication);  and  type  of  heart  disease  (divided
nto  ischaemic,  dilated,  hypertrophic,  arrhythmogenic  right
entricular  dysplasia  [ARVD],  electrical  disorders  or  none).
The  following  technical  data  were  collected:  venous
ccess  (cephalic  or  subclavian);  lead  position  (apex  or  sep-
al);  type  of  Sprint  Fidelis  lead  (single-coil  models  6930
passive]  or  6931  [active]  and  dual-coil  models  6948  [pas-
ive]  or  6949  [active]);  number  of  implanted  leads;  device
ocation  (right  or  left  side);  and  prepectoral  or  subpectoral.
The  date  of  implantation,  the  date  of  the  last  follow-
p  or  patient’s  death  (with  cause  of  death),  the  use  of
ppropriate  and  inappropriate  therapy  during  follow-up
antitachycardia  pacing,  shocks  or  both)  and  the  date  of
he  Sprint  Fidelis  lead  failure  were  all  recorded.  Lead
ailure  was  deﬁned  as  one  or  more  of  the  following:  asymp-
omatic  increase  in  pacing  or  high-energy  circuit  impedance
t  follow-up  or  detected  by  the  lead  integrity  alert  (LIA)
lgorithm;  asymptomatic  abrupt  decrease  in  right  ventricu-
ar  sensing;  non-sustained  ventricular  ﬁbrillation  episodes
orresponding  to  short  intervals  (asymptomatic);  and  inap-
ropriate  therapy  with  shocks  (symptomatic).
tatistical analysis
tatistical  analysis  was  performed  using  SAS  version  9.2  (SAS
nstitute  Inc.,  Cary,  NC,  USA).  Descriptive  statistics  were
sed  to  analyse  the  data.  For  continuous  variables,  data  are
xpressed  as  means  (ranges)  ±  standard  deviations.  Time-to-
vent  analyses  were  conducted  using  Kaplan—Meier  rates,
o  estimate  the  percentage  of  patients  with  no  events  at
peciﬁed  time  intervals.  Cox  models  were  used  to  identify
redictors  of  lead  fracture,  ﬁrst  by  univariate  analysis,  test-
ng  the  factors  one  by  one,  and  then  in  a  model  with  an
scending  stepwise  selection  of  variables.  Hazard  ratios  and
heir  95%  conﬁdence  intervals  are  provided  for  both  uni-
ariate  and  multivariable  analyses.  No  replacements  were
ade  in  the  case  of  missing  data.  The  level  for  statistical
igniﬁcance  was  deﬁned  as  a  P  value  <  0.05.
p
p
c
Lesults
rom  December  2004  to  November  2007,  1022  patients
eceived  a  Sprint  Fidelis  lead  in  the  six  participating  centres,
epresenting  20.3%  (1022/5024)  of  all  Sprint  Fidelis  leads
mplanted  in  France  during  the  same  period.  Follow-up  was
ensored  at  the  end  of  March  2012,  and  36  patients  were
xcluded  for  missing  data.
The  baseline  characteristics  of  the  remaining  986
atients  are  reported  in  Table  1.  Brieﬂy,  the  mean  age  of  the
atients  was  60.9  ±  10.6  years,  82%  were  men,  and  the  indi-
ation  was  primary  prevention  in  58%  of  patients.  The  mean
VEF  was  0.32  (range  0.15—0.70)  and  the  most  frequent
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Table  2  Univariate  analysis.
Factors  P
Female  gender  0.69
Age  at  implantation  (<  40  years;
40—60  years;  >  60  years)
0.0001
Group  1 (IHD,  DCM)  versus  group  2  (HCM,  ARVD,
channelopathies,  normal  heart)
0.012
LVEF  (<  35%;  35—55%;  >  55%) 0.035
Subpectoral  versus  prepectoral 0.0006
Lead  model:  6930  versus  6931,  6948,  6949  0.009
Passive-ﬁxation  versus  active-ﬁxation  0.05
Single-coil  lead  versus  dual-coil  lead  0.15
Single-coil,  active-ﬁxation  lead  versus
dual-coil,  active-ﬁxation  lead
0.20
Single-coil,  active-ﬁxation  lead  versus
dual-coil,  passive-ﬁxation  lead
0.82
Number  of  implanted  leads  (1,  2,  3)  0.20
Lead  position:  apex  versus  septum  0.35
Left  or  right  device  position  0.76
Venous  access:  cephalic  versus  subclavian  0.92
Delivered  therapies  (yes/no)  0.18
CRT  indication  0.45
Implanting  centre  0.16
ARVD: arrhythmogenic right ventricular dysplasia; CRT: cardiac
resynchronization therapy; DCM: dilated cardiomyopathy; HCM:
hypertrophic cardiomyopathy; IHD: ischaemic heart disease;
Table  3  Predictors  of  lead  fracture  on  multivariable
analysis.
Factors  Hazard  ratio  95%  CI  P
Age
<  40  years  1
40—60  years  0.53  0.29—0.98  0.0005
>  60  years  0.45  0.24—0.84  0.0005
Device  insertion
Prepectoral 1
Subpectoral  2.35 1.29—4.28 0.025
Lead  model
6949  1
6931  1.07  0.51—2.22
6948  1.81  0.79—4.19
6930  3.47  1.13—10.7  0.049
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FLVEF: left ventricular ejection fraction.
underlying  cause  was  ischaemic  heart  disease.  Aetiologies
were  subsequently  stratiﬁed  into  two  groups:
• group  1,  comprising  patients  with  ischaemic  heart  disease
or  dilated  cardiomyopathy;
• group  2,  consisting  of  patients  with  other  aetiologies
(hypertrophic  cardiomyopathy,  ARVD,  channelopathies  or
an  apparently  normal  heart).
Four  different  types  of  Sprint  Fidelis  leads  were
implanted,  most  commonly  the  single-coil,  active-ﬁxation
(6931)  lead  (53%)  and  the  dual-coil,  active-ﬁxation  (6949)
lead  (39%).
The  mean  follow-up  duration  was  51.4  ±  20  months,  with
a  mean  rate  of  Sprint  Fidelis  lead  fracture  of  11.2%  at  the  end
of  follow-up.  The  incidence  of  lead  fracture  increased  with
time,  with  a  lead  fracture  incidence  of  1.2%  at  1  year,  reach-
ing  20.7%  at  5  years  In  the  group  of  118  patients  with  Sprint
Fidelis  lead  failure,  the  failure  was  detected  in  70  patients
(59%)  after  inappropriate  shocks  caused  by  lead  failure,  in  33
(28%)  by  LIA,  and  in  15  (13%)  at  the  time  of  routine  3-month
follow-up.  Overall,  148  patients  had  Sprint  Fidelis  lead  revi-
sion:  114  (76%)  for  lead  failure;  16  (11%)  for  prophylactic
lead  change  at  the  time  of  generator  replacement;  and  18
(13%)  for  non-lead-related  reasons,  mainly  infection  (n  =  10).
Four  patients  with  lead  failure  underwent  ICD  deactivation
with  no  lead  revision  (patient’s  choice,  n  =  2;  terminal  ill-
ness,  n  =  2).The  results  of  the  univariate  analysis  of  lead  failure
predictive  factors  are  shown  in  Table  2.  Brieﬂy,  univari-
ate  analysis  revealed  a  higher  incidence  of  lead  fracture
with  the  single-coil,  passive-ﬁxation  6930  lead  compared
i
a
i
aCI: conﬁdence interval.
ith  that  in  other  models  (P  =  0.009),  and  an  increased  risk
f  lead  fracture  with  passive-ﬁxation  leads  (the  6930  and
848  models)  compared  with  active-ﬁxation  leads  (the  6931
nd  6949  models)  (P  <  0.05);  however,  there  was  no  dif-
erence  between  single-coil  and  dual-coil  leads  (P  =  0.82).
our  other  factors  were  identiﬁed  as  risk  factors  for
ead  fracture:  patient  age  <  40  years  (P  =  0.0001);  group  2
atients  (P  =  0.012);  patients  with  LVEF  > 55%  (P  =  0.035);
nd  subpectoral  implantation  (P  =  0.0006).  For  subpectoral
mplantation,  the  statistical  signiﬁcance  appeared  only  after
 years.
In the  multivariable  analysis,  three  predicting  fac-
ors  were  found  to  be  associated  with  lead  fracture:
atient  age  <  40  years  (P  =  0.0005);  subpectoral  implan-
ation  (P  =  0.025);  and  the  presence  of  a  single-coil,
assive-ﬁxation  6930  lead,  compared  with  the  dual-coil,
ctive-ﬁxation  6949  lead  (P  =  0.049)  (Table  3).  The  other
assive-ﬁxation  lead  (the  dual-coil  6948  model)  was  not
ssociated  with  a statistically  signiﬁcant  increased  inci-
ence  of  lead  fracture.
iscussion
his  multicentre  French  registry  of  almost  1000  patients
mplanted  with  all  four  types  of  Sprint  Fidelis  lead,  with  a
ong  follow-up,  conﬁrms  the  important  fracture  incidence
f  the  Sprint  Fidelis  lead.  This  failure  rate  continues  to
ncrease  with  time,  reaching  >  20%  at  5  years,  the  highest
ate  reported  so  far.  Predictors  of  lead  failure  were  young
ge,  subpectoral  implantation,  and  the  presence  of  the
ingle-coil,  passive-ﬁxation  6930  lead.
ncreasing rate of lead failure with time
he  results  of  our  study  show  that  the  rate  of  Sprint
idelis  lead  fracture  increases  with  time,  with  a  fracture
ncidence  of  7.4%  at  3  years,  13.9%  at  4  years,  and  20.7%
t  5  years.  This  failure  rate  is  higher  than  that  reported
n  the  Medtronic  Carelink  cohort  [13].  This  discrepancy,
lready  underlined  by  Birnie  et  al.  [11],  may  result  from
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s24  
emographic  differences,  because  the  Medtronic  cohort
ncluded  only  North  American  patients;  or  it  may  be  lead
elated,  as  our  study  included  a  signiﬁcant  proportion  of
ll  four  Sprint  Fidelis  leads,  whereas  the  Medtronic  cohort
ncluded  type  6949  leads  almost  exclusively.
Cheung  et  al.  [14]  investigated  the  temporal  trend  of  lead
ailure  and  found  a  stabilization  of  failures  after  3  years,
ransitioning  from  an  exponential  to  a  linear  model.  In  con-
rast,  in  accordance  with  our  data,  larger  cohorts  [11]  have
escribed  an  accelerated  rate  of  failure.  Furthermore,  of
he  major  published  data  [11,14—28],  our  series  reports  the
ighest  rate  of  failure  at  5  years  of  follow-up,  emphasizing
he  magnitude  of  the  potential  clinical  implications.  A  com-
arison  of  the  failure  rates  in  several  major  Sprint  Fidelis
ead  cohorts  is  shown  in  Table  4.
ead failure predictive factors
he  univariate  analysis  revealed  that  age  <  40  years,  heart
isease  aetiology  other  than  dilated  cardiomyopathy  or
schaemic  heart  disease  (group  2  patients,  i.e.  patients
ith  subnormal  or  normal  left  ventricle),  and  subpectoral
mplantation  were  predictors  of  lead  fracture,  whereas  the
ultivariable  analysis  conﬁrmed  that  only  age  <  40  years  and
ubpectoral  implantation  were  independent  predictors  of
racture.  Passive-ﬁxation  leads  were  associated  with  an
ncreased  risk  of  failure  in  the  univariate  analysis,  but
his  ﬁnding  was  only  conﬁrmed  for  the  single-coil,  passive-
xation  lead  in  the  multivariable  analysis.
Young  age  at  implantation  was  consistently  associated
ith  lead  failure  [16,19,22].  Our  study  found  that  a  cut-off
f  40  years  was  optimal  for  risk  stratiﬁcation.  Young  age  may
e  associated  with  heart  disease  aetiology  other  than  dilated
ardiomyopathy  or  ischaemic  heart  disease,  and  higher  LVEF,
actors  already  associated  with  an  adverse  lead  outcome.
evertheless,  young  age  was  conﬁrmed  in  the  multivariable
nalysis  as  a  potent  risk  factor,  while  the  association  with
eart  disease  aetiology  was  non-signiﬁcant.  Morrison  et  al.
19]  suggested  that  a  signiﬁcant  number  of  lead  failures
ccur  around  times  of  intense  physical  activity,  a  potential
onfounder  in  this  population.
Subpectoral  implantation  has  been  proposed  as  an  alter-
ative  implantation  technique  for  pacemakers  and  ICDs,  and
as  been  described  as  a  technique  of  choice  in  children  [29].
ernstein  et  al.  [25]  recently  described  a  strong  association
etween  subpectoral  implantation  and  lead  failure  in  Sprint
idelis  leads.  In  our  series,  subpectoral  implantation  had  a
elative  risk  of  adverse  lead  outcomes  of  2.35,  the  potential
echanism  being  the  lead  angulation  as  it  crosses  the  pec-
oralis  muscle.  It  should  be  noted  that  the  adverse  effect
f  subpectoral  implantation  only  became  signiﬁcant  after
 years  of  follow-up.
Several  studies  [11,27],  including  the  Medtronic  Product
erformance  Report  [13],  have  investigated  the  correla-
ion  between  lead  type  and  failure  rate.  Birnie  et  al.  [11]
ound  that  the  failure  rate  of  passive-ﬁxation  leads  was
igniﬁcantly  less  than  that  of  active-ﬁxation  leads,  in  a
tudy  population  with  an  overwhelming  majority  (93.9%)
f  active-ﬁxation  leads.  These  data  are  replicated  by  the
edtronic  database,  with  6-year  survival  rates  that  are
igher  for  the  dual-coil,  passive-ﬁxation  6948  lead  com-
ared  with  any  active-ﬁxation  lead  model.  Data  for  the
p
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930  lead  are  scarce,  as  it  is  under-represented  in  most
eries.  Frey  et  al.  [27]  reported  an  annual  failure  rate  of
.9%  in  a  population  implanted  exclusively  with  passive-
xation  leads.  This  failure  rate  is  lower  than  rates  reported
n  populations  mainly  implanted  with  active-ﬁxation  leads.
ecently,  Vollmann  et  al.  [28],  investigating  a  population
f  414  passive-ﬁxation  leads,  found  failure  rates  similar
o  those  reported  with  active-ﬁxation  leads.  In  contrast,
n  our  study,  both  univariate  and  multivariable  analysis
evealed  that  the  lowest  incidence  of  lead  failure  was
ncountered  with  dual-coil,  active-ﬁxation  leads,  whereas
he  highest  incidence  was  seen  with  the  single-coil,  passive-
xation  6930  lead.  There  was  also  a  non-signiﬁcant  tendency
owards  more  events  with  single-coil  leads  versus  dual-coil
eads.  These  conﬂicting  data  come  from  studies  with  an
nbalanced  representation  of  each  lead  type.  Nevertheless,
espite  theoretical  explanations  for  a  lower  fracture  rate
ith  passive-ﬁxation  leads,  by  virtue  of  the  simpler  lead
echnology,  we  believe  that  the  risk  is  at  least  as  high  as
ith  active-ﬁxation  leads,  and  that  this  should  prompt  the
ame  level  of  precaution  in  these  patients.
Multiple  implantation-related  predictive  factors  have
een  investigated  in  other  studies  (Table  4).  Farwell  et  al.
15]  and  Birnie  et  al.  [11]  both  found  that  non-cephalic
enous  access  was  associated  with  the  worst  outcome,
ut  this  was  not  conﬁrmed  in  our  study.  This  differ-
nce  may  be  related  to  various  venous  access  routes,
ith  the  majority  of  access  routes  being  cephalic  in  our
tudy.  Interestingly,  in  the  study  by  Bernstein  et  al.  [25],
ephalic  vein  access  was  not  found  to  be  protective,  in
 population  with  a  similar  access  route  prevalence  to
urs.  Morrison  et  al.  [19]  speciﬁcally  studied  X-ray  lead
ariables,  such  as  the  angulation  of  the  lead  entering
he  subclavian  vein  or  the  sleeve-clavicle  length,  but  did
ot  ﬁnd  any  correlation  with  an  increased  risk  of  fail-
re.
A recent  subgroup  analysis  of  the  Resynchroniza-
ion/Deﬁbrillation  for  Ambulatory  Heart  Failure  (RAFT)
tudy  [26]  looked  speciﬁcally  at  a  population  receiving
ither  an  ICD  or  a  cardiac  resynchronization  therapy  (CRT)
lus  deﬁbrillator  (CRT-D)  device,  and  showed  that  receiving
 CRT-D  and  having  more  than  two  leads  was  associated  with
 2.4-fold  risk  of  Sprint  Fidelis  failure.  In  contrast,  Frey  et  al.
27]  found  no  correlation  with  concomitant  CRT  implanta-
ion.  In  our  population,  37%  of  patients  underwent  CRT  and
9%  had  more  than  one  lead,  but  no  signiﬁcant  statistical
ssociation  was  found  between  number  of  leads  and  risk
f  failure.  Likewise,  other  risk  factors,  such  as  generator
eplacement,  higher  LVEF  or  female  sex  did  not  reach  sig-
iﬁcance.  Coming  from  six  high-volume  centres,  data  were
niform  and  no  centre-related  bias  was  identiﬁed  (data  not
hown).
Differences  in  risk  factors  for  fractures  could  be  caused
y  differences  in  the  design  of  registries  (single  or  multi-
entre),  as  well  as  differences  in  patient  characteristics,
ncluding  types  of  lead.  With  a  long  follow-up  and  a  large
opulation  of  patients,  we  have  shown  that  young  age,
ubpectoral  implantation,  and  the  6930  lead  models  are
redictive  factors  for  lead  failure.  At  the  time  of  any
aterial-related  procedure  (i.e.  ICD  replacement),  inser-
ion  of  a new  ICD  lead  should  be  discussed  more  strongly
n  patients  with  predictive  factors  for  lead  failure.
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Table  4  Major  studies  reporting  rate  and  predictive  factors  of  Sprint  Fidelis  lead  failure.
Study  Number
of  leads
Type  of  lead  Follow-up  Predictive  factors  Failure  rate
Farwell  et  al.  2008  [15]  480  6949  19.8  months  Non-cephalic
venous  access;
higher  LVEF
3.5%  at
19.8  months
Hauser  et  al.  2009  [16]  848  NA  27  ±  11  months  10.6%  at  3  years
Faulknier  et  al.  2010  [17]  426  6949,  69%;  6931,
31%
2.3 ±  1  years  Higher  LVEF  9%  at  3  years
Van  Rees  et  al.  2010  [18] 372  6931,  61%;  6949,
26%;  6948,  12%;
6930,  1%
2.5  ±  1  years 11%  at  42  months
Morrison  et  al.  2010  [19]  451  6949,  97%;  6931,
2.4%;  6948,  0.4%
21 months  Age  <  50  years  10.7%  at
30  months
Hauser  et  al.  2011  [20]  1023  6949,  98%  2.8  years  Younger  age;
female  sex;
disease  group
(HCM,  ARVC,
channelopathies)
13%  at  4  years
Arias  et  al.  2011  [21]  378  6949,  61%;  6948,
39%
31 ±  14  months  Higher  LVEF;
centre  of
implantation
3.9%  at  3  years
Girerd  et  al.  2011  [22]  269  6931,  78%;  6949,
21%
2.8 years  Age  <  62.5  years  12.5%  at  2.8  years
Birnie  et  al.  2012  [11]  3169  6949,  82%;  6931,
12%;  6948,  6%
5 years  Centre  of
implantation;
female  sex;
non-cephalic
access;  previous
lead  fracture
16.8%  at  5  years
Tzogias  et  al.  2012  [23]  971  6949  46.3  months  None  9.7%  at  5  years
Lovelock  et  al.  2012  [24]  479  6949  60.2  months  Generator
exchange
14.3%  at  5  years
Cheung  et  al.  2012  [14]  604  6949,  98%  3.3  ±  1.7  years  Female  sex  14.7%  at  5  years
Bernstein  et  al.  2012  [25] 176  6949;  6931  35  ±  11  months  Right-sided
implantation;
subpectoral
implantation
5.7%  at  3  years
Parkash  et  al.  2012  [26]  818  NA  40  ±  20  months  CRT  therapy;
presence  of  two  or
more  leads
5.5%  at  40  months
Frey  et  al.  2012  [27]  139  6948  49  ±  15  months  4.2%  at  5  years
Vollmann  et  al.  2013  [28]  414  6948,  98%;  6930,
2%
39 ±  28  months  Previous  ICD  lead
failure;  presence
of  an  atrial  lead
14.4%  at  5  years
This  study  986  6931,  53%;  6949,
39%;  6948,  6%;
6930,  2%
51.4  ±  20  months  Age  <  40  years;
subpectoral
implantation;  lead
6930  (versus  lead
6949)
20.7%  at  5  years
ARVC: arrhythmogenic right ventricular cardiomyopathy; HCM: hypertrophic cardiomyopathy; ICD: implantable cardioverter-deﬁbrillator;
LVEF: left ventricular ejection fraction; NA: not available.
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tudy limitations
ur  study  is  limited  by  its  retrospective  nature.  Further-
ore,  we  studied  Medtronic  Sprint  Fidelis  leads  exclusively
nd  did  not  compare  them  with  other  models.  Only  a  minor-
ty  of  lead  failures  were  conﬁrmed  by  ex  vivo  analysis.
onclusion
his  large,  independent,  multicentre  study  of  986  Sprint
idelis  leads  revealed  that  the  lead  failure  rate  was  high  and
ontinued  to  increase  with  time,  exceeding  20%  at  5  years.
ndependent  predictors  of  lead  failure  were  young  age,  sub-
ectoral  implantation,  and  the  presence  of  the  single-coil,
assive-ﬁxation  6930  lead.
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